Phase II clinical study of hexestrol (NSC-9894).
D005260:Female; D006589:Hexestrol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*
D006589:Hexestrol